NCT00874120已完成3 期
Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 116
- 主要终点
- Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).
研究概览
简要总结
Randomized, placebo-controlled double-blind, crossover design study; 116 subjects randomized on Day 1 to obtain 98 completed subjects. Study will be composed of a 7-day period of therapy with randomized active or placebo treatment with a subsequent 6-8 day washout period, followed by a second 7-day period of double-blind therapy with the other agent. Ambulatory blood pressure measurement will be performed beginning on Day 7 of each treatment period following administration of the study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, male or female volunteers must be 18 years or older, with a Body Mass Index (BMI) between 19-30 inclusive [BMI = weight (kilograms)/height (meters squared)].
- •Clinical laboratory tests (complete blood count, blood chemistries, urinalysis), Human Immunodeficiency Virus (HIV) antibodies, hepatitis B surface antigen, hepatitis C antibody must be within normal limits or clinically acceptable to the Investigator/Sponsor.
- •Drug screen for drugs and alcohol with a high potential for abuse must be negative at screening.
- •Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations, procedures or participation.
- •Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks (14 days) prior to study participation and for two weeks (14 days) after the end of their study participation.
- •Subjects must have normal or clinically acceptable physical exam and Electrocardiogram (ECG) intervals (PR, QRS, QT and QTc) on 12-lead ECG (recorded at 25 millimeters/second [mm/s]).
- •Subjects must have a mean after 5 minute of rest sitting systolic/diastolic office blood pressure ≤ 138/88 millimeters of mercury (mmHg).
- •Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure ≤ 128/78 mmHg from non-dominated arm
- •Females must have the urine or serum pregnancy test (Human Chorionic Gonadotropin) that is negative at Screening and Day 1 of Period
- •Female subjects of childbearing potential must be using medically acceptable birth control measures.
- •Subjects must understand the dosing schedule.
- •Subjects must be able to read and write in English.
排除标准
- •Subjects must not have any significant medical condition which, in the judgment of the Investigator, is a contraindication to the use of phenylephrine HCl, might interfere with the study or requires treatment expected to affect the blood pressure. These may include hyperthyroidism, hypothyroidism, uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, prostatic hypertrophy.
- •Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration.
- •Subjects who have received an investigational drug within 30 days prior to study dosing.
- •Subjects who are, appear to be, or are known, current or former drug addicts or alcoholics.
- •Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.
- •Subjects who are positive for HIV antibodies.
- •Subjects who have a clinically significant history of food or drug allergy.
- •Subjects who have a known allergy or intolerance to phenylephrine HCl.
- •Females who are pregnant, nursing or unwilling to use/practice adequate contraception (hormonal, Intrauterine Device, barrier method, etc.).
- •Subjects taking topical or oral decongestant products within 7 days of Visit
- •Subjects taking antihypertensive medication.
- •Subjects taking monoamine oxidase inhibitors.
- •Subjects taking tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine)
- •Subjects taking antithyroid medication (e.g. propylthiouracil, methimazole, iodides).
研究组 & 干预措施
Phenylephrine HCl Extended-Release tablets 30 mg
Experimental
Phenylephrine HCl Extended Release tablets 30 mg
干预措施: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax).
时间窗: 24 hours after final dose of each 7-day treatment period.
Five hour (hr) range around the Tmax was defined as approximately 2 hours before to approximately 2 hours after the Tmax, including Tmax. The parameters will be compared between active drug and placebo using analysis of variance (ANOVA). The 95% 2-sided Confidence Interval (CI) on the difference between treatments will also be presented.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Randomized, Double-Blind, Placebo-Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-050 Administered to Healthy, Postmenopausal Women.Muscular dystrophyMusculoskeletal - Other muscular and skeletal disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12619000318189Keros Therapeutics Australia Pty Ltd48
进行中（未招募）
1 期
Clinical trial to investigate the effects of clonazepam on patients with ARID1B-related intellectual disability.ARID1B-related intellectual disabilityEUCTR2019-003558-98-NLCentre for Human Drug Research40
已完成
4 期
Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures in patients with ARID1B-related intellectual disabilityNL-OMON52899Centre for Human Drug Research40
进行中（未招募）
1 期
Randomised double-blinded control adaptive trial to measure of the effectiveness of acipimox in patients with Mitochondrial MyopathyEUCTR2018-002721-29-GBewcastle upon Tyne Hospitals NHS Foundation Trust120
进行中（未招募）
1 期
Heart Failure study in patients with reduced heart function.Heart Failure with Reduced Ejection FractionEUCTR2018-002239-11-NLMyoKardia Inc.56